Adchara Janyou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adchara Janyou has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Aida Moohammadaree
School of Medicine, Mae Fah Luang University, Chiang Rai, Thailand
1 shared publication- Apichart Suksamrarn
Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Ramkhamhaeng University, Bangkok, Thailand
1 shared publication Chainarong Tocharus
Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
1 shared publicationJiraporn Tocharus
Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
1 shared publicationNarudol Teerapattarakan
1 shared publication- Phateep Hankittichai
School of Medicine, Mae Fah Luang University, Chiang Rai 57100, Thailand; Cancer and Immunology Research Center (CIRC), Mae Fah Luang University, Chiang Rai 57100, Thailand
1 shared publication
Latest Publications
- 12 March 2025
- Published by Elsevier in South African Journal of Botany
- Vol. 180, 171-184
Preclinical neuropharmacological effects of Centella asiatica-derived asiaticoside and madecassoside in Alzheimer's disease
- 12 March 2025
- Published by Elsevier in South African Journal of Botany
- Vol. 180, 171-184
Preclinical neuropharmacological effects of Centella asiatica-derived asiaticoside and madecassoside in Alzheimer's disease
- 28 April 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (2) , 1064-1071
Effects of isosakuranetin on cerebral infarction and blood brain barrier damage from cerebral ischemia/reperfusion injury in a rat model
This study investigated the effects of isosakuranetin (5,7-dihydroxy-4′-methoxyflavanone) on cerebral infarction and blood brain barrier (BBB) damage in cerebral ischemia and reperfusion (I/R) in a rat model. The right middle cerebral artery was occluded for 2 h followed by reperfusion. The experimental rats were divided into five groups: a sham, or control group; vehicle group; and 5 mg/kg, 10 mg/kg, and 20 mg/kg bodyweight isosakuranetin-treated I/R groups. After 24 h of reperfusion, the rats were tested using a six-point neurological function score. The percentage of cerebral infarction was evaluated using 2,3,5-triphenyltetrazolium chloride (TTC) staining. BBB leakage was determined by Evan Blue injection assay and brain morphology changes were observed under light microscopy following staining with hematoxylin and eosin (H&E). The results of neurological function score revealed that isosakuranetin reduced the severity of neurological damage. A dose of 10 and 20 mg/kg bodyweight of isosakuranetin significantly decreased the infarct volume. All three doses of isosakuranetin significantly decreased Evan Blue leakage. The penumbra area of the I/R brains revealed the characteristics of apoptotic cell death. Therefore, isosakuranetin-treated I/R attenuated the brain damage from cerebral I/R injury and further investigation of the mechanisms warrant further investigation to assist in the development of protective strategies against cerebral I/R injury in clinical trials. Communicated by Ramaswamy H. Sarma
- 28 April 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (2) , 1064-1071
Effects of isosakuranetin on cerebral infarction and blood brain barrier damage from cerebral ischemia/reperfusion injury in a rat model
This study investigated the effects of isosakuranetin (5,7-dihydroxy-4′-methoxyflavanone) on cerebral infarction and blood brain barrier (BBB) damage in cerebral ischemia and reperfusion (I/R) in a rat model. The right middle cerebral artery was occluded for 2 h followed by reperfusion. The experimental rats were divided into five groups: a sham, or control group; vehicle group; and 5 mg/kg, 10 mg/kg, and 20 mg/kg bodyweight isosakuranetin-treated I/R groups. After 24 h of reperfusion, the rats were tested using a six-point neurological function score. The percentage of cerebral infarction was evaluated using 2,3,5-triphenyltetrazolium chloride (TTC) staining. BBB leakage was determined by Evan Blue injection assay and brain morphology changes were observed under light microscopy following staining with hematoxylin and eosin (H&E). The results of neurological function score revealed that isosakuranetin reduced the severity of neurological damage. A dose of 10 and 20 mg/kg bodyweight of isosakuranetin significantly decreased the infarct volume. All three doses of isosakuranetin significantly decreased Evan Blue leakage. The penumbra area of the I/R brains revealed the characteristics of apoptotic cell death. Therefore, isosakuranetin-treated I/R attenuated the brain damage from cerebral I/R injury and further investigation of the mechanisms warrant further investigation to assist in the development of protective strategies against cerebral I/R injury in clinical trials. Communicated by Ramaswamy H. Sarma